News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Khalid El Bairi: Low-Dose anti-PD-(L1) ICIs are also effective and may improve access, especially in resource-limited settings
Khalid El Bairi/LinkedIn
Jun 8, 2025, 08:48

Khalid El Bairi: Low-Dose anti-PD-(L1) ICIs are also effective and may improve access, especially in resource-limited settings

Khalid El Bairi, Founder of The Cancer Biomarkers Working Group, shared an article on LinkedIn:

“This is our latest publication in the European Journal of Cancer in which we demonstrated that low-dose anti-PD-(L1) immune checkpoint inhibitors are also effective and may improve access, especially in resource-limited settings.
Find more here.”

Expanding Access to Cancer Immunotherapy: A Systematic Review of Low-Dose PD-(L)1 Inhibitor Strategies.

Authors: Pablo Jiménez-Labaig, Failah Mohamed, Nur Jihan Irwan Tan, Ilves Sanna, Khalid El Bairi, Shah Zeb Khan, Amol Akhade, Teresa Amaral, Dario Trapani, Amol Patel, and Kevin J. Harrington.

You can read the full article on European Journal of Cancer.

Khalid El Bairi: Low-Dose anti-PD-(L1) ICIs are also effective and may improve access, especially in resource-limited settings

More posts featuring Khalid El Bairi.

Amol Akhade Amol Patel anti-PD-L1 cancer Cancer Immunotherap Dario Trapani European Journal of Cancer Failah Mohamed fight against cancer Global fight against cancer ICIs Ilves Sanna Immune Checkpoint Inhibitors Kevin J. Harrington. Khalid El Bairi Low-Dose PD-(L)1 Inhibitor Nur Jihan Irwan Tan OncoDaily Oncology Pablo Jiménez-Labaig Shah Zeb Khan Teresa Amaral The Cancer Biomarkers Working Group
Special Coverage
Blog
Jul 20, 2025, 12:10
David Gandara: Provocative Data Supporting Treatment Beyond Progression by Julia Rotow
Blog
Jul 20, 2025, 11:52
Chuck Stravin: What We Did in Boston This Week at KCRS2025 Will Change Lives Worldwide
Blog
Jul 20, 2025, 11:35
Jo Parkes: What Happens When You Bring Three Oncologists, a Pharmacist, and a Microphone Together
Blog
Jul 20, 2025, 11:27
Mustafa Saleh: Discussing Intra Tumoral Viral Signature Association with RCC Immune Phenotypes at KRCS25
Blog
Jul 20, 2025, 11:27
Erika Hamilton: Takeaways from Reshma Mahtani Updates in Early Stage HR+ BC
Blog
Jul 20, 2025, 11:17
Petros Grivas: Way to Go to Help Us Conquer Cancer!
Blog
Jul 20, 2025, 10:28
ALK Positive Awarded Colin Barton with Spirit of Courage Award
Radiotherapy
Jul 20, 2025, 10:28
Understanding the Role of Radiation Therapists
Oncolibrary
Jul 20, 2025, 10:24
How Aging Populations Are Reshaping Global Cancer Trends or The Silent Shift
Blog
Jul 20, 2025, 10:17
Rahul Bhargava: New Era in Myeloid Malignancy Diagnostics
Science
Jul 20, 2025, 10:08
Myeloma Paper of the Day, July 20th, Suggested by Robert Orlowski
Insight
Jul 20, 2025, 09:30
ASCO 2026 Presidential Theme: Dr. Eric Small’s Vision to Translate Science Into Global Cancer Impact